ADMS - Earnings call transcript Q3 2019 | Adamas Pharmaceuticals Inc

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Ladies and gentlemen, thank you for standing by and welcome to the Adamas Third Quarter 2019 Financial Results Conference Call. [Operator Instructions].

I would now like to hand the conference over to your speaker today, Peter Vozzo of Investor Relations. Please go ahead, sir.

Peter Vozzo

Thank you, Sonya, and good afternoon, everyone.

would forward-looking remind to statements uncertainties. I call that risks begin, contain will which we like everyone to this and Before are subject statements are or Any events, statements. expectations future regarding forward-looking results forward-looking note of date statements Please call. these reflect opinions of this only our the as that light as no undertake required in by revise information or these forward-looking or law. We new update future to statements obligation of events except forward-looking or the statements filed to factors discussed differ actual materially implied that by Risk contained those today under concerning detail such Information greater caption results in are XX-Q in in SEC, could from Form Factors. the cause our especially with

I'll Neil McFarlane, now to over the turn Chief Executive call Officer.

Neil McFarlane

new be is first Chris our afternoon. you, our Shreedhar, November the of the with Chris to Rajiv XXXX here in Chief Chief Good Officer. Officer since Commercial to Thank role Officer; to welcome at Financial in our leadership assumed quarterly Chief leadership Financial and with my Officer; team. Peter. Chief Medical senior Dr. delighted Vijay Adamas, I'm Adamas. This call being Patni, role Prentiss, after pleased Chris and I'm a

exciting look mission towards helping dyskinesia an much in to What have continue a few focus mission. have a with and long-term with pipeline deep to is discovered position. And patients excited months and With since cash with we I'm September. with is a company joining this to GOCOVRI this company and joined Adamas therapeutic, success. own at Adamas in the Adamas beliefs, healthy aligned has disease bringing Parkinson's late-stage drive team been a very patient, busy I I've that committed business been my on novel and It's to a forward OFF. I've a to strong impressed place the a

an focused success top additional for Phase III X are GOCOVRI on for we we priorities, with data line in sclerosis walking GOCOVRI As our multiple which delivering and year-end, patients remain indication approach for driving commercial impairment.

sequential continued considerable growth, and commercial continuing of potential. a very initiatives. lives, and for During community. foundation the spent and there's realize a works my our significant time provides to is impact patient a strongly quarter-over-quarter I hear which GOCOVRI percentage its What prescriptions makes on patients' total quarter, future in the tremendous physician GOCOVRI a I've opportunity daily

will has already to commercial taken steps Vijay As committed and is Progress made, sustainable learning strategy adjusting to discuss, team GOCOVRI increase value. to being several our and the adoption. we're build

in prepared program his remarks. focus excited of our support the sclerosis III multiple demand half see disease review are from MS primary need Phase walking patients GOCOVRI is in market. study significant potential given actively the Rajiv development preparing data we the if December, during with increasing Phase on unmet Parkinson's GOCOVRI will We established for entry in and this our second dyskinesia, While the amongst are expect about our INROADS approved highly III the for with a to into patients market. we impairment

effects the treatment data meaningful large options. to initial our address prior study can from we to ensure disciplined our whom for that anticipate discontinued are seeing be Therefore, tried there approach to We forward who that top strategy. will the dalfampridine a on we We commercial and to data a take assessing look line will focuses to on Adamas treatment III rigorous those Phase that focus unmet note have to to impact finalizing INROADS deliver significant patients. important It's limited needs. and INROADS

Chief remember Commercial the started Officer in as I'll to June. over who Vijay, may now turn call our you

Vijay Shreedhar

then provide of QX call. I good is my overview comments made our today. you QX highlighted on with the update priorities progress will I to and Neil, great with earnings an everyone. and It on the speaking strategic an you, Thank on begin afternoon, performance we've be the in

that exclude free QX versus rose increase XX% paid the QX XXXX of GOCOVRI and of Total an last product X% trial X,XXX from prescriptions of program versus scripts, to representing year. approximately

XX% again, GOCOVRI. driven not place a did is free bringing have at the trial the to encouraging. at refilling of value XX% we paid quarter the experience to highlighting While until growth clinical nonadopters strong that approximately last this XX% patients. year and help in XX is program This year, in at total growth months by first to remains continues XX% be versus X gain patients steady months, and to GOCOVRI Persistence prescriptions to

prescriptions quarters. XXX Conversion quarter, did to included new latter consistent were the approximately in receive starts in a on rates new and prescriptions modest QX, patients who not XX% free both There free for elaborate will previous topic patients patient registering increase moment. a which XX%, paid trial. trial to a This from generally trial with the was between of I the part paid free also steady held in

Our growth use slight analysis in by amongst the performance of reveals significant decline prescriptions was established new some from that offset a writers quarter's in writers.

process by We share our increase enhance sales are targeting force of to voice improving prescriber offices operational in satisfaction. of our high-prescriber our effectiveness addressing optimizing the to and fulfillment these this

among fulfillment trial focusing new X-week increasing force free customer centricity our sales process. starts grow prescribers by breadth, the enhancing through depth, prescribers to of new and of plan by the addition optimization program leveraging current use activity We of the and on patient

with levodopa are OFF. on of Parkinson's dyskinesia approved therapy. patients are Our reduce profile highlight increasing the in other Parkinson's clinical and dyskinesia. only that for And the medications FDA-approved trials X to dyskinesia interactions for to increase in there disease our disease, Phase OFF of is medications dyskinesia continue treatment the functional remain proven significantly for about that with generally want clinically and product patients leaders episodes OFF, treatment we time GOCOVRI. reinforce both no the to GOCOVRI III of ON Parkinson's for indicated thereby highly optimistic I with differentiated thought and patients clinical potential helping

QX to have pleased in our report business. initial strategic areas. of priorities notable these call we progress I August, assessment my highlighted On I each based that in am earnings X our of on made

First, health we care urgency relationship to the impact and impact treat recognize the disease. effective its disruptive educating increasing OFF to of on practitioners the its are dyskinesia, by of to treatment Parkinson's

supplemented is a launched awareness We content care The specifically new treating initiative digital of have not recently on physicians Web a be Parkinson's practitioners being patients. how has dyskinesia prioritized focuses proactive for routine force. number disease during on patient disruption delivered obvious disruption our updated OFF This anchored targeting and by on and consultation living of discussion. materials health many of sales with high activities this campaign a the may to aspects impact by daily caused patients' and that initiative unless on

are we customer and centricity is reliable improving of simple, one that transparent. Second, our the process fulfillment to deliver

have Towards center points in end-to-end of analysis to our this leakage address instituted conducted we and them. changes several end, at an fulfillment the quarter

a introducing reduce simplified form submission. are during prescription to errors We vastly

customers. also treatment. GOCOVRI patients point have launched to initiate X, care created is feedback receiving from of streamline and a for positive they as as single We coordinators team This serve team, communication clinics on and October of a contact dedicated

result XX-day weeks. rate of increase a in last conversion X the have in an the these As seen initiatives, early we

our Our trained to sales been about also force fulfillment to process transparency. to increase has deliver education clinics

X-week trial increasing free awareness program. of are our we Third,

of through and marketing for prescription reminder new in have have We new branded digital physician program created increased and messaging resources the this offices. form

evaluate among to nonadopters to serve this continue trial and We of all elements patients to better. program expand of the drug

look for forward initial details were our areas three to and every plans focus, prioritized our in sharing these to future calls. examine additional of element While execution. we and about I strategic continue operational strategy

review now Rajiv will over I trial. INROADS turn it to to our

Rajiv Patni

we I'm December or III data bedtime. first from impairment the half trial X deliver doses X to that milligrams report XXXX. XX at This by and of X our in data QHS placebo-controlled on MS study remain provide track to double-blind, top second XX safety happy of of INROADS GOCOVRI: taken Thanks, milligrams and Phase will efficacy walking III Phase Vijay. line

responders at treatment a speed baseline in XX-foot after test. increase each as the is The A who defined primary XX as least is in group weeks walking timed efficacy proportion responder from a walk patient double-blind by of measured experienced endpoint the treatment. XX% of

X-minute the approach and include pivotal and error Up or endpoints Timed the assumption trial. Go, X control any are type the and test patient-reported power the the walk TUG; Secondary to MSWS-XX. The the for standard outcome,

of described; and It is placebo-controlled INROADS. placebo-controlled important studies: study, be which similar a to development that just to pivot I second which program this INROADS, will recall consists X

of GOCOVRI If successful, studies the measures Given walking timed of may is plan the data from data If approval, the we initiate a certain walk required. for pooling expect indication in submission greater would XX-foot to compared XXXX. MSWS-XX INROADS valuability from support XXXX. placebo-controlled both test, be like in the launch sNDA this we and study second new studies to both to

We INROADS thoughtfully criteria defined have success data. for

First are to pristine and the we all from data. database this queries are In we prior follow-up, quality. of lock. lost data reliability to conclusions will database the top That answered and our patients minimized in are is, line not foremost, ensure need missing way, data be to satisfactorily confident

effect consistency other efficacy The clinically dose evidence that across of include size walking is success walking all on response, an and and criteria a statistically speed persuasive measures.

reported from should data II the important, what equally be safety Phase with the study. and Lastly par we on

timed XX-foot XX-foot is measure registration patients to sclerosis Chris, over since will functions. or First, endpoint a received, an have on functional "Why I impairment, test of not part fatigue?" walk how efficacy MS in as a MS-related question I recognizes of the as recently market is FDA timed GOCOVRI is with test, study the the by the direct address Before Walking call MSFC. a impairment measured of effect composite, did the it hand The we patient walk we established a need. in walking multiple

in far, not disabilities, fatigue fatigue-related there based the MS-related and a no a multifactorial MS is, of to consequence note our precedent including Second, in living registration the with fatigue important is measure endpoint walking for on impairment. It thus literature, but of view, that MSFC, efficacy is the is trials. primarily part

at XXXX reviewed walking Congress, we day fatigue progresses. As the constant contrast, In AAN as the remains the throughout increases day. impairment

impairment of like would is walking I motor impairment. to a type Third, emphasize

data suggest that demonstrated on signal and walking PD motor Phase convincingly via a on positive given its II motor The impairment MS have We efficacy on the effect OFF effect speed. reduces impairment dyskinesia. in GOCOVRI

and aligned the maintained INROADS amantadine temporal later QHS of concentrations impairment profile the unique this dosing, PK and the in With PD with are morning look to the the low motor in top through GOCOVRI year. achieved day from with is both high data We night. during the forward MS, is, that pattern line concentrations

will With hand that, I to over Chris. the call

Christopher Prentiss

good everyone. Thanks, afternoon, and Rajiv,

in my with role. me to First, to I'd like forward priorities look supporting of this certainly here accomplish to at new investors. transition the the working needs we thank to and everyone ensuring team our key for Adamas I meet our

Now discuss for third quarter. results the the let's

product were X% million year. XXXX quarter of $XX.X in same the Third million, quarter XX% sales last $XX.X increase a increase over second XXXX quarter and a over

X first of product of compared $XX.X to for months an GOCOVRI period XXXX, the XX%. the million same For increase XXXX, were $XX.X of sales million

$XX.X million Regarding was or compared or second of a third as to the for for of quarter loss XXXX. overall million loss the Net of results. per our million our to $X.XX quarter share were $X.XX R&D INROADS third loss operating per the $XX.X net quarter enrollment a in $X.X loss of $X the third quarter. expenses for trial million prior compared in completed the quarter share a

quarter the Despite SG&A due within previous primarily to is and million XXXX, company's $XX.X in annual guidance. expenses of expect second to compared SG&A charges million fall This to both transition. $XX.X our these XXXX. of were the related to expense quarter onetime we During charges, onetime CEO increase third the R&D

Overall were million. and investments down burn quarter third the was for cash XX, at $XX slightly of from XXXX, approximately as Cash September quarters approximately million. prior $XXX

filing a have had to housekeeping, believe going is active we today, shelf previously part our in Therefore, have we it shelf in is of expiring place. shelf later important what with we registration this Finally, amount consistent good financial forward. an as month. are And

Let Neil. me call over now turn the back to

Neil McFarlane

Chris, you, and Operator? I'll now Rajiv Vijay. open line Thank the for questions.

Operator

Instructions]. [Operator

from comes of Leerink. Marc question first Our SVB Goodman

Roanna Ruiz

earlier. one is Mark. have Ruiz line on the on your a question This Roanna comments for quick of I

think ongoing I prescribers. prescribers growth new mentioned offset in the you

Or give could was can why ongoing other be on you a So around is their curious, bit might color of I that? GOCOVRI? prescribers lowering any elaborate there use you

Neil McFarlane

part I in maybe this think and start tremendous Vijay get where about learning quarters. into generally Anna, it we Neil. to think patient for adapting Maybe line is that Thanks stable and really our towards in breadth. the quickly increase off our question. to was some go. starts specifics, I'll QX general, on were I'll executing previous the we the with over When I new just hand made of need able that to be to Vijay? but of and progress listening, to this strategy quarter

Vijay Shreedhar

Neil. you, Thank

me begin received comes free are reminding starts, and the Let receiving new define and prescriptions of trial on current we and writers new paid patient how patient patients patients right? starts And enrolling the in New the by you trial. combination calculate who writers. sum of without this free from a new

QX an force in growth for QX. to So of I'm report area the third versus was base we There XX% our that was in pleased our that focus new expanded sales in expanding base. quarter, prescribers prescriber a major significantly.

prescribers So in prescriber we some offset a slight This GOCOVRI. to was growth starting new offices. had high-volume trial in decline a by healthy

Now why is that?

is a routine the multiple urgency space. highly And It relatively of in sensitive with discuss patients is complex, Parkinson's visits discussions is this right promotionally and relatively players to low. and This are in now. the And crowded. dyskinesia There progressive. OFF physicians, is disease space

we do sales our to force these high-prescriber matters. in what So offices

educating these that why is improving them very sales we to key increase we our communicating free And our increasing voice back relative refine trial product differentiated these growth. and to us our to of action So force treat clinics of have that the to optimistic have that on physicians profile. in to get the focus about taken and confident fulfillment share areas and and remain we a because will our targeting urgency

Roanna Ruiz

more you're of for you metrics sort there prescriptions. process can program And share Got question paid color their evaluate around it. to one like That's streamlining move regarding helpful. that patients the from free Are And when have I to just some tracking drug success? any those?

Neil McFarlane

Vijay?

Vijay Shreedhar

of center a to end-to-end analysis in We the process is fulfillment prescription have at drug. receives our faxed patient a done an form from when when

that We're So it order have process for office ways. those we each a And this of mapped there one variety are a to a to multiple in drug steps out. make the functionally see physician's have get patient. simplified measuring rate trial for in to easier It processes work it we cleanest in takes of prescription. -- in terms paid the fulfillment their way of Why period free a of time conversion to all is the The process. XX-day days? way through measure to rate to in prescriptions XX that

that So the as in few I XX-day said, an of the conversion rate we're weeks seeing in last improvement quarter.

Neil McFarlane

I this. add one thing might just on

to about, across to GCCs leakage As we we important executing the Vijay that To leakage over. in largest the month, areas large it's the be fulfillment of we opportunities process at fact areas bringing we're were part his he's that last analyzed able to see point, our that the but various went the fulfillment points now. leakage process, of prioritize still big looked the to onboard live It it, fix. a talked are that additional was feel the quickly. these add that and improve doesn't We could on mean tactics we

Operator

And our from of Josh comes Schimmer Evercore question next ISI.

Joshua Schimmer

you growth think a But the it the to possible quarter-over-quarter it long until do back of how It's so? the do was the to so? to recovered range? third might script much quarter to Up take do X,XXX it closer per couple to from get take might second And ago, nicely quarter. growth X,XXX. is What quarter script quarters into

Neil McFarlane

Vijay?

Vijay Shreedhar

what you Let said there. me noting just begin with

barriers trial increasing levers because barriers awareness of approached focus and And notable it, up we first. key set changes largest key address The and quarter. three focus to to free therefore, progress of urgency use way identified our program demand. quickly in the we increasing the was top focusing we by of our and areas instituted on in We these increasing our as to improving we that these this treat, terms areas have made fulfillment

phases. remarks, signs There to positive. early changes, implemented been largely what So coming early implemented. have saw are and the The we in these you of my as these more changes been have reception in prepared just have

and about As fast are to as remain prospects execute learn continuing Neil time. over to we mentioned we -- in we as adapt, our continue can, and remarks, as his we execute optimistic

So that's over why our focus remains and will And starting increasing we're depth. changes to the breadth make I impact think time. have

Operator

of Jaffray. And Piper our comes Amsellem from question next David

David Amsellem

Just a couple.

is to the rate state with two realistically? terms but how in one. Number expect Sorry what now. you So And this, said you the if steady is it of where that's missed improvements, sampling, be conversion do do you're number co-pay to that. long going to So your just right of a is sampling? the for what's just now average strategy? I commercial execution remind And mean this be you lastly, be feature on think patients? going then permanent us I

Neil McFarlane

conversion. is was weeks. as are lot week this point top I our one a the with "We about a has our transparent, assistant last make field talked said, had to than Maybe David, make was reliable, with more educate XX%. Great. through. on single been it, of MDS-er. start three instituted prescribers the Vijay the Neil. process It's less really fulfillment having executing I'll was what steady to it again, at office, after organization And appreciate in that medical for I it to it field of XX% an And held contact." the coming is leaving only our simplify That of

he if can better the real is questions, think us to to to hand simplified the of benefits that do format. rest the I'll And see some job. having So I Vijay there over a

Vijay Shreedhar

we And previous as carefully we a and by encouraged very talked up see. tracking on the been have steadily, add that to to see just question tracking Neil XX-day we signs well. about, that quite rate, what early fulfillment To we're the

say your for an In intended growth. not trial our aspect. lot to the unending be has room question a still base terms about program this of samples, I I would that of remind is the you prescriber free will physical that on

And system our program writers into unlocking to full current get new That of So is free of to progress opportunity depends are we're And to see. depth of spread. as having keep increase potential the more we'll GOCOVRI. GOCOVRI we breadth in an trial among we long program very the intended see but good writers do. further increasing utilization, for also the is us to the pleased place in both what breadth on as trialing which

asked the $XX question about we're the you Now or from to data, pleased that out-of-pocket seeing expenses of time, patients GOCOVRI, that XX% are our copays a report that received through. their the come less. of I'm latest

as So that possible. see as very continue, to available we we course, encouraged that. to pleased and committed about making are patients to to of GOCOVRI And remain broadly

Operator

next Ken question Cowen our comes of And Company. from Cacciatore and

Kenneth Cacciatore

I the to you're happening when It they were seems have to Or understand question. fulfillment trying want may get simplistic was And you that going there, center previously? been Like was at your just -- are of control employees something form to But have motivation and were correct. they what control the what an I'm now? I not complete might overly fixed? make process. getting did sure employees? seems they wrong that your the their employees in a that like was

if had an that about of Is talked a get it issue employees, it to like form. it came seems it form everyone try and more So when a work clarify heck you to Because clinician one done. a like from your to would simplistic standpoint?

in And an you process. that impact wanted control not problem? the sampling, I OSMOLEX at of are maybe is is really of understand part their to then So that and all? also issue Or their fulfillment just now the and complete

Vijay Shreedhar

Sure.

process. address fulfillment let in the me first terms So question of the

the is people well physician team reaching who them. patient, a single Our employees different office to for They as end-to-end of different are patient. to revealed of AllianceRx. These right? care are were had out coordinator GOCOVRI contact process analysis people, the of contact that stage point different every reaching to of The as dedicated a and/or the of a the process physician's a point

the they as GOCOVRI quarterbacks the coordinating business, AllianceRx who steps issues players might essentially so the However, that than much within the serve with with streamlined the communication dedicated pop quicker the have to are of They fully we we to to is help communication resolution various might the highly system among them. very and streamline tightly seen there's are process a customer, that and before. the up the of

To let GOCOVRI was us. what physical from activity We of presence question product. with to and our the remarks, you fact competition. that what a me OSMOLEX. tell begin continue highly see samples by do your But physicians They heard of see prepared differentiated as

we're We dyskinesia. for dyskinesia OFF have the time. and profile proven ones the ones with ones that a benefit only And the with very the only of with both only FDA differentiated that indication and QHS We're clinical ON treatment in a we're bedtime increasing dosing. in an

impact right space. So physicians see we us this an continue don't differentiated. as competitive product a in highly of to now And see

Neil McFarlane

Ken, maybe in the Adamas or incentives product. to of simplifying that They're the fulfillment. that. making Adamas and When asked trained of ours, employees one they're on aligned patients -- process our the are sure terms what are thing add -- on around they not they're you product were are, question get just not whether I'll

think ensure to a deliver. it's there's be a to want matrix -- that we So tight delivering guys these to I would and able what are

that deliver it and there's clear consistency how make it they're feel to delivering we ourselves. want I between tight like a would what So we

Operator

And Tim of William next Blair. question our from comes Lugo

Timothy Lugo

growing same been And have are with call. where past few first going the think the quickly maybe is prescriptions I that the that's following a prescribers Do we've around losing previous on, question, X,XXXs. TRxs the rate prescribing some on quarters? new still lead to well around growing in at to you it in subscribers not on the sequentially seen as that guess the Neil, as of top GOCOVRI. Congratulations, previously

higher think in give and maybe growing details just around therefore sticky? they're that. more XXXs more me I some the they're However, quality and

Neil McFarlane

take going An from to in I'm part that Tim, to talked as prescriber away being shake XX% a we at QX of where prescribers. consistent we the fact stick increase the is depth this which that nothing about were, the to at. breadth really a stab first just put a to base one, broaden effort we on able growing of

I The actually, actually think somebody to outstanding fulfillment has did program that. the first of where means team treat, working. to the its opportunity an we've breadth. doing able this And -- this going, job we're to I when think, increase able urgency is get in that in is free seen we're time type -- that that trial means and that

now validating So we it's kind base, have broad when tactics. we can deep our now. current that go of But

allows Rx it improve. for the to So TRx and

and to some can I'll maybe switch he details. into Vijay get So additional

Vijay Shreedhar

an urgency utmost us. Increasing demand for is

we base So that to and misconception appropriately depth. We of Neil there as QX. the prescriber front. a no allocating in with targeting said, force are the And ensure let the on that our be great can success both And therefore on aspect happen. increasing, saw breadth breadth sales we are focused both

the We now. And have on X the that areas we and there. in that are will us firmly progress get believe some our depth work to key focus aspect, right do on focused we

Timothy Lugo

into these prescribers? just some the new sounds SG&A back spend maybe there on because expect bit level side it maybe Or be deepening you Should investment deeper into optimization, spend? continue just these well? of new a to as tie this we might Could as same the you're prescribers around with to like Okay. SG&A

Neil McFarlane

take assessment has refining accelerate I'll great this we we job to his Chris able quick in feel targeting we'll growth in can his get see targeting if at sized. need to He's done of as at going. again, a on and adequately So he's be call. looking a moving, engaged we're Vijay We the step, and this PD. what point

shape. I actually so I'll hand today, pretty voice So the SG&A on can think here have a Chris good But too. you in it to over we're side

Christopher Prentiss

we're that we the yes, that the key our to not continue priority he business. really our this make truly look things is and completely drive PD need We've Obviously, tactics focused the And on. Neil. we're and that on. to focus continue to, at but key team the Vijay focus Thanks, the wants resources to on asked to reallocating overspend. But to priority, yes, priorities

So look what's important really and Vijay of job continuing at good done the to business. a just team drive has to

Vijay Shreedhar

we terms now, right of where necessary force optimizing we share in targeting is the focused versus provide to mix of on are And voice marketing sales marketing the digital need.

Timothy Lugo

in the -- will Okay. And INROADS success. I around one your of what as kind if could pipeline for Thank question. you view commentary and you maybe a sneak

November. However, pristine the terms set good we'll a early that there you come you first given idea that just get seems data how now have will like speak Can be December? you confident conduct the it of probably point in and it's of data, trial maybe pristine about are as to trial conduct

Neil McFarlane

get Thank too. Rajiv? in you here, We'll you.

Rajiv Patni

the for thanks question. So

very PD in are our the mentioned, confident as the experiences program. I with We And on Neil trial say that based conduct.

is in Phase which So did III step we will achieve high-quality in data, PD. readout. it We data X any

MS. in do will it We

Operator

next And Ram H.C. of Wainwright. comes question Selvaraju our from

Raghuram Selvaraju

regarding new wanted coming from to just get the and what additional the are I So of profile clarity where onboard some that are patients. the patients those are new prescribers bringing

which If other words, product base new the please? are patients who the is? you to that, prescriber on What's the could profile, on from elaborate the of in coming

Neil McFarlane

Vijay?

Vijay Shreedhar

have prescribed new volumes treat question, some prescribers that trialing drug who high-volume we prescribers We just see lower some the for -- thanks first of prescribers mix not are of Parkinson's previously, time for as who that disease the are The Ram. see the patients. well as

get we mix of where terms from. So we in see a the breadth

Raghuram Selvaraju

retention introduced think first respect what what Okay. the rate regarding previously to this that at original And in those about regarding the new that we now, And at expectations XX% talking it in that with months. the was has time to the months retention X a keeping the profile you originally and were I'm that has then product GOCOVRI retention Or long-term XX XX% provided is and about If XX% the at at figures particular, emerged anticipated? you dynamics look picture we with profile. overall roughly emerged? is

Vijay Shreedhar

Yes.

a So are very we patients the to pleased a stay how address question, and persistency on from perspective perspective in drug. both that terms compliance of

metrics, of of in a patients So drug. the key They continued highlighting that both the drug. in the continue stay terms see we to see value on those

So condition of what we've for pleased we're this nature, with very a seen.

Raghuram Selvaraju

then the is question pertaining to And indication. Okay. last the INROADS

GOCOVRI potential have be implications which does would conditions other for of beneficial as related words, and in there the beyond on be impact positive explorations utility evidence of point other an any In of impairment, the impairment use those there possibility to supporting are MS? in in contexts? this potentially specifically would walking Given that indications ameliorator walking

Neil McFarlane

Dr. Patni?

Rajiv Patni

And I areas can GOCOVRI. benefit us have Neil's company, PD. the maximizing in GOCOVRI demonstrate said the a where course, motor study a will it comment, I this an patient first where with remarks an to in Appreciate there we in say hope that question. it, that GOCOVRI should about think motor because show my opening is pivotal impairment, effect prepared we And disease about in size. additional and population make as large back is If in of MS. have as two We to impairment, effect

if So yes we it, is then answer. see the

where seriously will GOCOVRI population explore We a could provide that distinct patient patient else benefit. in

Raghuram Selvaraju

point. clarificatory one just And Great.

certain with a the is study pooling achieve broadly confirmatory what you speaking putative about statistical data the of whether just implied was and You INROADS just you meant pooling of trial. previously were if was to respect analysis? what of robustness? Or But prespecified to clarify possibility talking data subgroup pooling can from

Rajiv Patni

with Pooling as treatment an the meant appreciate certain variability. PRO, just in the measures general, in of example, inherently and be in most being is pool data MSWS-XX. data to patient-reported estimate. clarity. particular, the MSWS-XX to have PROs, the request respect to a that outcome, I secondary high efficacy to with effect I And precise What and more point straightforward for -- the deal way the

Operator

this call McFarlane Ladies the turn question-and-answer over session. would any now closing remarks. Neil to and our gentlemen, like back does I for to conclude

Neil McFarlane

completing I've dyskinesia that for thank remain received driving disease growth Adamas. along of great half since for and want continuing focused second on joining quarterly calls. at to Phase upcoming forward dialogue everybody with Parkinson's I and providing Sonya. December. investor priorities: INROADS welcome look in GOCOVRI a you, Have our top We the X III Thank conferences patients study OFF; in and updates warm to with afternoon. We our the the

Operator

Ladies and participating. concludes gentlemen, Thank for this call. you conference today's

disconnect. now may You

Adamas Pharmaceuticals (ADMS) 7 Nov 192019 Q3 Earnings call transcript